Teva Projects $16.8B to $17.0B Revenue for 2025 at J.P. Morgan Conference
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2h ago
0mins
Source: Newsfilter
- Transformation Strategy Progress: At the J.P. Morgan Healthcare Conference, Teva showcased its 'Pivot to Growth' strategy, projecting revenues of $16.8 billion to $17.0 billion for 2025, indicating ongoing efforts in innovative biopharmaceuticals and market confidence.
- Innovation Driving Growth: Key innovative brands like AUSTEDO® and AJOVY® are propelling Teva's growth, with clinical pipeline assets expected to further enhance financial outlook, thereby strengthening competitive positioning in the market.
- Financial Performance Outlook: Teva anticipates adjusted EBITDA of $4.8 billion to $5.0 billion for 2025, with an operating margin between 26.2% and 27.1%, reflecting positive progress in cost management and profitability.
- Future Outlook: Teva commits to disciplined capital allocation and securing an investment-grade credit rating for 2026 and beyond, with expectations for moderate growth by 2030, underscoring the company's focus on long-term sustainability.
Analyst Views on TEVA
Wall Street analysts forecast TEVA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for TEVA is 29.25 USD with a low forecast of 28.00 USD and a high forecast of 32.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 32.510
Low
28.00
Averages
29.25
High
32.00
Current: 32.510
Low
28.00
Averages
29.25
High
32.00
About TEVA
Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
